Article Text

Download PDFPDF
Review: dipyridamole given with or without aspirin reduces recurrent stroke

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with a history of ischaemic cerebrovascular disease, does dipyridamole given with or without aspirin reduce the risk of recurrent stroke?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Internal medicine ★★★★★★☆ Neurology ★★★★☆☆☆ Haematology ★★★★☆☆☆


Embedded ImageData sources:

Cochrane Library (Issue 4, 2002), Medline (1966–2001), EMBASE/Excerpta Medica (1980–2002), Web of Science (1981–2002), bibliographies of relevant articles, researchers, and a manufacturer of dipyridamole (Boehringer Ingelheim, Ingelheim, Germany).

Embedded ImageStudy selection and assessment:

randomised controlled trials (RCTs) in any language that evaluated dipyridamole for secondary prevention of stroke in patients with previous cerebrovascular disease. Study quality was assessed using criteria that included method of randomisation, concealment of allocation, completeness of follow up, and blinding of outcome assessment.

Embedded ImageOutcomes:

recurrent stroke (combined fatal and non-fatal), non-fatal stroke, combined fatal and non-fatal myocardial infarction (MI), vascular death, and a composite outcome of non-fatal stroke, non-fatal MI, and vascular death.


5 RCTs (n = 11 240) (mean age 65 y, 60% men) were included in …

View Full Text


  • For correspondence: Professor P Bath, University of Nottingham, Nottingham, UK.

  • Source of funding: no external funding.